Mid and South Essex Health and Care Partnership

NHS

SACUBITRIL VALSARTAN (ENTRESTO®) PRESCRIBING ADVICE AND GUIDANCE

Therapeutic indication

Sacubitril Valsartan (Entresto®) is licensed for the treatment of adults with symptomatic chronic heart failure with a reduced ejection fraction.

Selection criteria

- Symptomatic chronic heart failure with:
  - New York Heart Association (NYHA) class II to IV symptoms, and
  - a left ventricular ejection fraction of 35% or less on echocardiogram or equivalent function on alternative imaging not older than 12 months, and
  - On optimal medical therapy for HF including angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor-blockers (ARB) (mandatory), beta-blocker and mineralocorticoid receptor antagonists (spironolactone or eplerenone) for at least 3 months.
- Systolic blood pressure (SBP) ≥100 mmHg
- eGFR >30 ml/min/1.73 m^2
- Serum potassium <5.4 mmol/l

Contraindications

- Known history of angioedema related to previous ACEI or ARB therapy
- Hereditary or idiopathic angioedema
- Pregnancy
- Treatment should not be initiated in patients with serum potassium level >5.4 mmol/l or with SBP <100 mmHg
- eGFR <30 ml/min/1.73 m^2
- Severe hepatic impairment, biliary cirrhosis and cholestasis
- Sacubitril valsartan should not be co-administered with an ACEI or an ARB
- Concomitant use with aliskiren-containing medicinal products in patients with diabetes mellitus or in patients with renal impairment (eGFR <60 ml/min/1.73 m^2)
- Hypersensitivity to the active substances or to any of the excipients

Initiation and up-titration

- Initiation of sacubitril valsartan is to be undertaken by a Heart Failure specialist in primary or secondary care who has access to a Heart Failure multidisciplinary team.
- Sacubitril valsartan should not be co-administered with an ACEI or an ARB. Due to the potential risk of angioedema when used concomitantly with an ACEI, it must not be started for at least 36 hours after discontinuing ACEI therapy. For those taking an ARB, discontinue ARB and start sacubitril valsartan at next scheduled dose of ARB.
- Initiation and titration to stable maintenance dose will be undertaken by the Heart Failure specialist
- Starting dose and titration in those on established ACEI or ARB (after ceasing ACEI or ARB):
  - Initiate 49mg/51mg sacubitril valsartan twice daily for 2 to 4 weeks then
  - Increase to 97mg/103mg sacubitril valsartan twice daily thereafter
- Starting dose in those patients taking low dose ACEI or ARB:
  - Initiate 24mg/26mg sacubitril valsartan twice daily for 3 to 4 weeks then
  - The dose should be doubled every 3 to 4 weeks to the target of 97mg/103mg twice daily, as tolerated by the patient
- A starting dose of 24mg/26mg sacubitril valsartan should be considered in patients with moderate renal impairment (eGFR 30-60 ml/min/1.73 m^2).
- A starting dose of 24mg/26mg sacubitril valsartan twice daily should be considered for patients with SBP ≥100 to 110 mmHg.

- Monitoring of renal function, electrolytes and blood pressure to be undertaken after each dose titration.

Down-titration or discontinuation

Adjustment of concomitant medicinal products, temporary down-titration or discontinuation of sacubitril valsartan is recommended. If this happens in primary care, please discuss with Heart Failure specialist:

- If SBP <95 mmHg
- If symptomatic hypotension
- If eGFR decreases >35% at follow up
- If serum potassium >5.4 mmol/L at follow up

Transfer to primary care and monitoring

- Following titration to optimum tolerated dose, prescribing will be continued in primary care.
- Please ensure that previous ACEI or ARB treatment is removed from the repeat prescription template and not continued.
- Measure serum sodium, potassium and assess renal function every 6 months for signs of renal impairment or hyperkalaemia.
- Blood pressure should be monitored routinely.

Further prescribing information

- Please refer to the Summary of Product Characteristics (SPC) for further information regarding side effects, drug interactions and special warnings: http://www.medicines.org.uk/emc/medicine/31244
- Sacubitril Valsartan (Entresto®) has been approved by NICE (TA388): https://www.nice.org.uk/guidance/ta388

Patient support and information

- A patient information leaflet will be offered to patients to support treatment initiation of sacubitril valsartan therapy. Additionally, it will detail instructions to avoid concomitant ACEI or ARB and confirm advice for patients during sick days.

Primary care support

- GP to refer back to the specialist who has initiated sacubitril valsartan if there are concerns about contraindications, cautions, monitoring results or prescribing responsibilities.
- HF Consultant contact details for advice and support:
  Dr Savage secretary contact details: alex.lowry@nhs.net - 01268 524900 ext 4088

References	Summary of Product Characteristics (SPC): http://www.medicines.org.uk/emc/medicine/31244 NICE TA388 (April 2016) Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction: https://www.nice.org.uk/guidance/ta388 NICE guideline NG106 (September 2018) Chronic heart failure in adults: diagnosis and management: https://www.nice.org.uk/guidance/ng106
Acknowledgements	Mid and South Essex CCGs Medicines Management Teams
Version	1.0
Author	HCPMSEMOC working group
Approved by	MSEMOC; MSE Joint Committee
Date Approved	October 2021
Review Date	October 2026 or earlier subject to any new updates nationally